ZA200210160B - New bispidine compounds and their use in the treatment of cardiac arrhythmias. - Google Patents
New bispidine compounds and their use in the treatment of cardiac arrhythmias. Download PDFInfo
- Publication number
- ZA200210160B ZA200210160B ZA200210160A ZA200210160A ZA200210160B ZA 200210160 B ZA200210160 B ZA 200210160B ZA 200210160 A ZA200210160 A ZA 200210160A ZA 200210160 A ZA200210160 A ZA 200210160A ZA 200210160 B ZA200210160 B ZA 200210160B
- Authority
- ZA
- South Africa
- Prior art keywords
- formula
- compound
- alkyl
- het
- represent
- Prior art date
Links
- 206010003119 arrhythmia Diseases 0.000 title claims description 16
- 238000011282 treatment Methods 0.000 title claims description 13
- PTPQJKANBKHDPM-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonane Chemical class C1NCC2CNCC1C2 PTPQJKANBKHDPM-UHFFFAOYSA-N 0.000 title claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 154
- 150000001875 compounds Chemical class 0.000 claims description 146
- 125000003118 aryl group Chemical group 0.000 claims description 74
- 125000002947 alkylene group Chemical group 0.000 claims description 42
- 125000001424 substituent group Chemical group 0.000 claims description 40
- 229910052739 hydrogen Inorganic materials 0.000 claims description 38
- 229910052799 carbon Inorganic materials 0.000 claims description 36
- 125000005843 halogen group Chemical group 0.000 claims description 35
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 35
- -1 -OH Chemical group 0.000 claims description 33
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 28
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 239000012634 fragment Substances 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 230000006793 arrhythmia Effects 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 229910052717 sulfur Chemical group 0.000 claims description 4
- 239000011593 sulfur Chemical group 0.000 claims description 4
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims description 3
- 230000001746 atrial effect Effects 0.000 claims description 3
- SIHVSPXVPKLFAB-UHFFFAOYSA-N 2-(3-benzyl-3,7-diazabicyclo[3.3.1]nonan-7-yl)ethanol Chemical compound C1N(CCO)CC(C2)CC1CN2CC1=CC=CC=C1 SIHVSPXVPKLFAB-UHFFFAOYSA-N 0.000 claims description 2
- ASVNRQFCHFLEPS-UHFFFAOYSA-N 4-[3-(7-benzyl-2,4-dimethyl-3,7-diazabicyclo[3.3.1]nonan-3-yl)-2-hydroxypropoxy]benzonitrile Chemical compound CC1N(CC(O)COC=2C=CC(=CC=2)C#N)C(C)C(C2)CC1CN2CC1=CC=CC=C1 ASVNRQFCHFLEPS-UHFFFAOYSA-N 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- CUIFDVJEFHYCEM-UHFFFAOYSA-N n-[1-(7-benzyl-3,7-diazabicyclo[3.3.1]nonan-3-yl)-3-(4-cyanophenoxy)propan-2-yl]methanesulfonamide Chemical compound C1C(CN(CC=2C=CC=CC=2)C2)CC2CN1CC(NS(=O)(=O)C)COC1=CC=C(C#N)C=C1 CUIFDVJEFHYCEM-UHFFFAOYSA-N 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 6
- 150000001721 carbon Chemical group 0.000 claims 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N Azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 claims 1
- 102100028139 Oxytocin receptor Human genes 0.000 claims 1
- 101710103206 Oxytocin receptor Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- WNTGVOIBBXFMLR-UHFFFAOYSA-N bicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1C2 WNTGVOIBBXFMLR-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000002140 halogenating effect Effects 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 7
- 239000003416 antiarrhythmic agent Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000002336 repolarization Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- DLNAKYFPFYUBDR-UHFFFAOYSA-N (4-aminophenyl)-(7-benzyl-3,7-diazabicyclo[3.3.1]nonan-3-yl)methanone Chemical compound C1=CC(N)=CC=C1C(=O)N1CC(CN(CC=2C=CC=CC=2)C2)CC2C1 DLNAKYFPFYUBDR-UHFFFAOYSA-N 0.000 description 1
- DLNAKYFPFYUBDR-HDICACEKSA-N (4-aminophenyl)-[(1s,5r)-7-benzyl-3,7-diazabicyclo[3.3.1]nonan-3-yl]methanone Chemical compound C1=CC(N)=CC=C1C(=O)N1C[C@@H](CN(CC=2C=CC=CC=2)C2)C[C@@H]2C1 DLNAKYFPFYUBDR-HDICACEKSA-N 0.000 description 1
- FTABKDGWKNKXQJ-UHFFFAOYSA-N (4-chlorophenyl)-(7-propan-2-yl-3,7-diazabicyclo[3.3.1]nonan-3-yl)methanone Chemical compound C1N(C(C)C)CC(C2)CC1CN2C(=O)C1=CC=C(Cl)C=C1 FTABKDGWKNKXQJ-UHFFFAOYSA-N 0.000 description 1
- BKXNECYZQMFRLG-UHFFFAOYSA-N (4-imidazol-1-ylphenyl)-(7-propan-2-yl-3,7-diazabicyclo[3.3.1]nonan-3-yl)methanone Chemical compound C1N(C(C)C)CC(C2)CC1CN2C(=O)C(C=C1)=CC=C1N1C=CN=C1 BKXNECYZQMFRLG-UHFFFAOYSA-N 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- MGLHZAPOUJJKCP-UHFFFAOYSA-N 3-propan-2-yl-3,7-diazabicyclo[3.3.1]nonane Chemical compound C1NCC2CN(C(C)C)CC1C2 MGLHZAPOUJJKCP-UHFFFAOYSA-N 0.000 description 1
- SEOQYNBBMGIYOF-UHFFFAOYSA-N 4-[3-(7-benzyl-4-methyl-3,7-diazabicyclo[3.3.1]nonan-3-yl)-2-hydroxypropoxy]benzonitrile Chemical compound C1N(CC(O)COC=2C=CC(=CC=2)C#N)C(C)C(C2)CC1CN2CC1=CC=CC=C1 SEOQYNBBMGIYOF-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000018452 Torsade de pointes Diseases 0.000 description 1
- 208000002363 Torsades de Pointes Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- IBUGLHHGZLMWBM-UHFFFAOYSA-N [N].C1NCC2CNCC1C2 Chemical compound [N].C1NCC2CNCC1C2 IBUGLHHGZLMWBM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 229950005516 ambasilide Drugs 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- PMCPYLGCPSNSLS-FOLVSLTJSA-N bisaramil Chemical compound CCN1C[C@@H]2CN(C)C[C@H](C1)[C@@H]2OC(=O)C1=CC=C(Cl)C=C1 PMCPYLGCPSNSLS-FOLVSLTJSA-N 0.000 description 1
- 229950007885 bisaramil Drugs 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000011128 cardiac conduction Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- UXOFXTUCXRNLFA-UHFFFAOYSA-N phenyl-(7-propan-2-yl-3,7-diazabicyclo[3.3.1]nonan-3-yl)methanone Chemical compound C1N(C(C)C)CC(C2)CC1CN2C(=O)C1=CC=CC=C1 UXOFXTUCXRNLFA-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229960002926 tedisamil Drugs 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0002603A SE0002603D0 (sv) | 2000-07-07 | 2000-07-07 | New compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200210160B true ZA200210160B (en) | 2004-03-15 |
Family
ID=20280441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200210160A ZA200210160B (en) | 2000-07-07 | 2002-12-13 | New bispidine compounds and their use in the treatment of cardiac arrhythmias. |
Country Status (3)
Country | Link |
---|---|
US (1) | US20030212095A1 (sv) |
SE (1) | SE0002603D0 (sv) |
ZA (1) | ZA200210160B (sv) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9902270D0 (sv) * | 1999-06-16 | 1999-06-16 | Astra Ab | Pharmaceutically active compounds |
MX2010002266A (es) * | 2007-08-30 | 2010-03-25 | Takeda Pharmaceutical | Derivados de pirazol sustituidos. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2428792A1 (de) * | 1974-06-14 | 1976-01-02 | Knoll Ag | Neue antiarrhythmika |
DE3112055A1 (de) * | 1981-03-27 | 1982-10-07 | Basf Ag, 6700 Ludwigshafen | Bispidinderivate, ihre herstellung und diese enthaltende arzneimittel |
DE3234697A1 (de) * | 1982-09-18 | 1984-03-22 | Kali-Chemie Pharma Gmbh, 3000 Hannover | Neue diazabicyclo-(3,3,1)-nonane |
US5468858A (en) * | 1993-10-28 | 1995-11-21 | The Board Of Regents Of Oklahoma State University Physical Sciences | N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents |
SE9704709D0 (sv) * | 1997-12-17 | 1997-12-17 | Astra Ab | Pharmaceutically active compounds |
-
2000
- 2000-07-07 SE SE0002603A patent/SE0002603D0/sv unknown
-
2001
- 2001-07-04 US US10/332,103 patent/US20030212095A1/en not_active Abandoned
-
2002
- 2002-12-13 ZA ZA200210160A patent/ZA200210160B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20030212095A1 (en) | 2003-11-13 |
SE0002603D0 (sv) | 2000-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2877471B1 (en) | Spiro-fused piperidine derivatives for use as inhibitors of the renal outer medullary potassium channel | |
AU2009203598B2 (en) | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3- yl]phenyl} -2H-indazole-7-carboxamide | |
RU2737190C2 (ru) | Ингибиторы репликации вируса гриппа, способы их применения и использование | |
EP3087077B1 (en) | Inhibitors of the renal outer medullary potassium channel | |
CN110114071A (zh) | 含有取代的吡啶酮的三环化合物以及使用其的方法 | |
JP2016518432A (ja) | B型肝炎ウイルス感染症の治療および予防のための6−架橋ヘテロアリールジヒドロピリミジン類 | |
IL205142A (en) | Pyridinone derivatives, their use in curing and the pharmaceutical composition containing them | |
CN113227090A (zh) | 杂芳基二氢嘧啶衍生物和治疗乙型肝炎感染的方法 | |
CA2314490A1 (en) | Novel bispidine antiarrhythmic compounds | |
KR20210121044A (ko) | 치환된 폴리사이클릭 카복실산, 이의 유사체, 및 이의 사용 방법 | |
IL149108A (en) | Oxabispidine compounds, process for their preparation, pharmaceutical compositions comprising them and use thereof in the preparation of a medicament for the treatment of arrhythmia | |
ZA200305345B (en) | 3,7-Diazabicyclo(3.3.0)octanes and their use in the treatment of cardiac arrhythmias. | |
CN115515949A (zh) | 新型氨基嘧啶类egfr抑制剂 | |
ZA200610418B (en) | Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias | |
ZA200210160B (en) | New bispidine compounds and their use in the treatment of cardiac arrhythmias. | |
KR20010023724A (ko) | 프탈라진 유도체 및 발기기능 부전 치료제 | |
ZA200109796B (en) | New bispidine compounds useful in the treatment of cardiac arrhythmias. | |
CN116075502B (zh) | 用于治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法 | |
US20040023971A1 (en) | 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias | |
ES2935722T3 (es) | Derivados de indol y usos de los mismos | |
EP3830087A1 (en) | Heterocyclic compounds and their use in preventing or treating bacterial infections | |
ZA200109798B (en) | New bispidine compounds useful in the treatment of cardiac arrhythmias. | |
ZA200109800B (en) | New bispidine compounds useful in the treatment of cardiac arrhythmias. | |
NZ523540A (en) | New bispidine compounds and their use in the treatment of cardiac arrhythmias | |
CA2377325A1 (en) | New bispidine compounds useful in the treatment of cardiac arrhythmias |